정신과 질환에서의 임상 병기 및 조기 개입 = Clinical Staging and Early Intervention in Psychiatry

다국어 초록 (Multilingual Abstract)

There is increasing awareness of the limitations of the current diagnostic system in psychiatry. Clinical staging is another complementary method that make possible to rate the severity of the disease, and to use of appropriate stage-specific evidence-based interventions including early non-invasive intervention. This paper summaried previous studies about the development of clinical staging and the early intervention or prevention by using this staging method in psychiatry. Clinical staging in psychiatry can clarify which people are at risk of psychiatric disease and what novel therapeutic strategies are most likely to successfully achieve remission and reduce the risk of persistence and recurrence for patients in each stage.

목차 (Table of Contents)

• 서론
• 정신병적 장애(Psychosis)
• 우울 장애(Depressive Disorder)
• 양극성 장애(Bipolar Disorder)
• 치매(Dementia)
• 결론
• 참고문헌

참고문헌 (Reference)

• 1 노대영, "정신병 위험상태 : 관련된 문제와 향후 전망" 대한생물정신의학회 18 (18): 203-209, 2011
• 2 김병수, "다시 보는 알츠하이머병의 아밀로이드 가설" 대한생물치료정신의학회 20 (20): 173-186, 2014
• 3 Thal DR, "[(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer’s disease: specific detection of advanced phases of amyloid-β pathology" 11 : 975-985, 2015
• 4 Rickwood D, "Young people’s help-seeking for mental health problems" 4 : 218-251, 2005
• 5 Alzheimer’s Association Expert Advisory Workgroup on N, "Workgroup on NAPA’s scientific agenda for a national initiative on Alzheimer’s disease" 8 : 357-371, 2012
• 6 Thase ME, "When at first you don’t succeed:Sequential strategies for antidepressant nonresponders" 58 : 23-29, 1997
• 7 Ruini C, "Well-being therapy in school settings: a pilot study" 75 : 331-336, 2006
• 8 Boothby LA, "Vitamin C and vitamin E for Alzheimer’s disease" 39 : 2073-2080, 2005
• 9 Chou YY, "Ventricular maps in 804 ADNI subjects:correlations with CSF biomarkers and clinical decline" 31 : 1386-1400, 2010
• 10 Yung AR, "Validation of “prodromal”criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up" 105 : 10-17, 2008
• 11 Andrews G, "Using epidemiological data to model efficiency in reducing the burden of depression" 3 : 175-186, 2000
• 12 Camus V, "Using PET with 18F-AV-45 (florbetapir)to quantify brain amyloid load in a clinical environment" 39 : 621-631, 2012
• 13 Souery D, "Treatment resistant depression:methodological overview and operational criteria" 9 : 83-91, 1999
• 14 Sperling RA, "Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease" 7 : 280-292, 2011
• 15 Gross G, "The “basic” symptoms of schizophrenia" 155 : 21-25, 1989
• 16 Reichart CG, "The use of the GBI as predictor of bipolar disorder in a population of adolescent offspring of parents with a bipolar disorder" 89 : 147-155, 2005
• 17 Agius M, "The staging model in schizophrenia, and its clinical implications" 2010
• 18 Carlson GA, "The stages of mania: a longitudinal analysis of the manic episode" 28 : 221-228, 1973
• 19 Yung AR, "The prodromal phase of firstepisode psychosis: past and current conceptualizations" 22 : 353-370, 1996
• 20 Lewinsohn PM, "The prevalence and co-morbidity of subthreshold psychiatric conditions" 34 : 613-622, 2004
• 21 Berk M, "The potential utility of a staging model as a course specifier: a bipolar disorder perspective" 100 : 279-281, 2007
• 22 Fekadu A, "The maudsley staging method for treatment-resistant depression" 70 : 952-957, 2009
• 23 Lieberman JA, "The early stages of schizophrenia:speculations on pathogenesis, pathophysiology, and therapeutic approaches" 50 : 884-897, 2001
• 24 Meares A, "The diagnosis of prepsychotic schizophrenia" 1 : 55-58, 1959
• 25 Cantor-Graae E, "The contribution of social factors to the development of schizophrenia: a review of recent findings" 52 : 277-, 2007
• 26 Hardy J, "The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics" 297 : 353-356, 2002
• 27 Reisberg B, "The Global Deterioration Scale for assessment of primary degenerative dementia" 139 : 1136-1139, 1982
• 28 Hua X, "Tensor-based morphometry as a neuroimaging biomarker for Alzheimer’s disease: An MRI study of 676 AD, MCI, and normal subjects" 43 : 458-469, 2008
• 29 Calear AL, "Systematic review of schoolbased prevention and early intervention programs for depression" 2010
• 30 Miller TJ, "Symptom assessment in schizophrenic prodromal states" 70 : 273-287,
• 31 Hammad TA, "Suicidality in pediatric patients treated with antidepressant drugs" 63 : 332-339, 2006
• 32 Dubicka B, "Suicidal behaviour in youths with depression treated with new-generation antidepressants" 189 : 393-398, 2006
• 33 Fergusson DM, "Subthreshold depression in adolescence and mental health outcomes in adulthood" 62 : 66-72, 2005
• 34 Sadek N, "Subsyndromal symptomatic depression:a new concept" 12 : 30-39, 2000
• 35 Fava GA, "Subclinical symptoms in mood disorders:pathophysiological and therapeutic implications" 29 : 47-61, 1999
• 36 Fava GA, "Staging: a neglected dimension in psychiatric classification" 87 : 225-230, 1993
• 37 Cosci F, "Staging of mental disorders: systematic review" 82 : 20-34, 2013
• 38 Grande I, "Staging bipolar disorder: clinical, biochemical, and functional correlates" 129 : 437-444, 2014
• 39 Gama CS, "Staging and neuroprogression in bipolar disorder: a systematic review of the literature" 35 : 70-74, 2013
• 40 Cohen D, "Should the use of selective serotonin reuptake inhibitors in child and adolescent depression be banned?" 76 : 5-14, 2006
• 41 Berk M, "Setting the stage: from prodrome to treatment resistance in bipolar disorder" 9 : 671-678, 2007
• 42 Kral VA, "Senescent forgetfulness: benign and malignant" 86 : 257-260, 1962
• 43 Hetrick S, "Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents" 3 : 2007
• 44 Olin SC, "School teacher ratings predictive of psychiatric outcome 25 years later" 172 : 7-13, 1998
• 45 Li JQ, "Risk factors for predicting progression from mild cognitive impairment to Alzheimer’s disease: a systematic review and meta-analysis of cohort studies" 2015
• 46 Correll CU, "Research in people with psychosis risk syndrome: a review of the current evidence and future directions" 51 : 390-431, 2010
• 47 Huang KL, "Regional amyloid deposition in amnestic mild cognitive impairment and Alzheimer’s disease evaluated by [18F]AV-45 positron emission tomography in Chinese population" 8 : e58974-, 2013
• 48 Preti A, "Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness" 123 : 30-36, 2010
• 49 McGlashan TH, "Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis" 2006
• 50 Phillips LJ, "Randomized controlled trial of interventions for young people at ultra-high risk of psychosis:study design and baseline characteristics" 43 : 818-829, 2009
• 51 McGorry PD, "Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms" 59 : 921-928, 2002
• 52 Angermeyer MC, "Public attitude towards psychiatric treatment" 94 : 326-336, 1996
• 53 In-Albon T, "Psychotherapy of childhood anxiety disorders: A meta-analysis" 76 : 15-24, 2006
• 54 Pfennig A, "Psychotherapeutic interventions in individuals at risk of developing bipolar disorder:a systematic review" 8 : 3-11, 2014
• 55 Ryff CD, "Psychological wellbeing and ill-being: do they have distinct or mirrored biological correlates?" 75 : 85-95, 2006
• 56 Eaton WW, "Prodromes and precursors:epidemiologic data for primary prevention of disorders with slow onset" 152 : 967-972, 1995
• 57 Fava GA, "Prodromal symptoms in primary major depressive disorder" 19 : 149-152, 1990
• 58 Fava GA, "Prodromal stage of major depression" 1 : 9-18, 2007
• 59 Dowrick C, "Problem solving treatment and group psychoeducation for depression: multicentre randomised controlled trial" 321 : 1450-, 2000
• 60 Jarrett RB, "Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial" 58 : 381-388, 2001
• 61 van der Gaag M, "Preventing a first episode of psychosis:meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups" 149 : 56-62, 2013
• 62 McNamara RK, "Preventative strategies for early-onset bipolar disorder: towards a clinical staging model" 24 : 983-996, 2010
• 63 Hartlage SA, "Premenstrual dysphoric disorder and risk for major depressive disorder:a preliminary study" 57 : 1571-1578, 2001
• 64 Yung AR, "Prediction of psychosis: setting the stage" 191 : 2007
• 65 Yung AR, "Prediction of psychosis. A step towards indicated prevention of schizophrenia" 172 : 14-20, 1998
• 66 Cannon TD, "Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America" 65 : 28-37, 2008
• 67 Ewers M, "Prediction of conversion from mild cognitive impairment to Alzheimer’s disease dementia based upon biomarkers and neuropsychological test performance" 33 : 1203-1214, 2012
• 68 Cuijpers P, "Predicting the onset of major depression in subjects with subthreshold depression in primary care: a prospective study" 111 : 133-138, 2005
• 69 Fusar-Poli P, "Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk" 69 : 220-229, 2012
• 70 Schultze-Lutter F, "Predicting first-episode psychosis by basic symptom criteria" 4 : 11-22, 2007
• 71 Khachaturian ZS, "Perspective on the “2014 Report on the Milestones for the US National Plan to Address Alzheimer’s Disease”" 10 : S265-S268, 2014
• 72 Sarris J, "Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression" 73 : 81-86, 2012
• 73 Addington J, "North american prodrome longitudinal study: a collaborative multisite approach to prodromal schizophrenia research" 33 : 665-672, 2007
• 74 Wood SJ, "Neuroimaging and treatment evidence for clinical staging in psychotic disorders: from the at-risk mental state to chronic schizophrenia" 70 : 619-625, 2011
• 75 Daviglus ML, "National Institutes of Health State-of-the-Science Conference statement: preventing alzheimer disease and cognitive decline" Ann Intern Med 153 : 176-181, 2010
• 76 Group AR, "Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial" 68 : 1800-1808, 2007
• 77 Miller ER, "Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality" 142 : 37-46, 2005
• 78 De Craen AJ, "Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia" 161 : 114-120, 2005
• 79 Yung AR, "Mapping the onset of psychosis:the Comprehensive Assessment of At-Risk Mental States" 39 : 964-971, 2005
• 80 Chou YY, "Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer’s disease, mild cognitive impairment and elderly controls" 46 : 394-410, 2009
• 81 Puri BK, "MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment" 13 : 123-126, 2002
• 82 Meyer SE, "Long-term outcomes of youth who manifested the CBCL-Pediatric Bipolar Disorder phenotype during childhood and/or adolescence" 113 : 227-235, 2009
• 83 Amminger GP, "Long-chain ω-3fatty acids for indicated prevention of psychotic disorders:a randomized, placebo-controlled trial" 67 : 146-154, 2010
• 84 Geller B, "Lithium for prepubertal depressed children with family history predictors of future bipolarity:a double-blind, placebo-controlled study" 51 : 165-175, 1998
• 85 Lauber C, "Lay recommendations on how to treat mental disorders" 36 : 553-556, 2001
• 86 McGorry PD, "Issues for DSM-V: clinical staging: a heuristic pathway to valid nosology and safer, more effective treatment in psychiatry" 164 : 859-860, 2007
• 87 Alzheimers Dement, "Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease" 7 : 257-262, 2011
• 88 Ruhrmann S, "Intervention in the at-risk state to prevent transition to psychosis" 22 : 177-183, 2009
• 89 McGorry PD, "Intervention in individuals at ultra-high risk for psychosis: a review and future directions" 70 : 1206-1212, 2009
• 90 Ratheesh A, "Instruments that prospectively predict bipolar disorder - A systematic review" 179 : 65-73, 2015
• 91 Bond L, "Individual, family, school, and community risk and protective factors for depressive symptoms in adolescents: a comparison of risk profiles for substance use and depressive symptoms" 6 : 73-88, 2005
• 92 Murphy JM, "Incidence of major depression:prediction from subthreshold categories in the Stirling County Study" 68 : 251-259, 2002
• 93 Wong DF, "In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18FAV-45(florbetapir [corrected] F 18)" 51 : 913-920, 2010
• 94 Keller MB, "Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression" 44 : 348-360, 1998
• 95 Rowe CC, "Imaging beta-amyloid burden in aging and dementia" 68 : 1718-1725, 2007
• 96 Kovacevic S, "Highthroughput, Fully Automated Volumetry for Prediction of MMSE and CDR Decline in Mild Cognitive Impairment" 23 : 139-145, 2009
• 97 Depue RA, "General behavior inventory identification of unipolar and bipolar affective conditions in a nonclinical university population" 98 : 117-, 1989
• 98 Marder SR, "Fluphenazine vs Placebo Supplementation for Prodromal Signs of Relapse in Schizophrenia" 51 : 280-, 1994
• 99 Murray J, "FDG and amyloid pet in cognitively normal individuals at risk for late-onset Alzheimer’s disease" 4 : 15-26, 2014
• 100 Niendam TA, "Exploring predictors of outcome in the psychosis prodrome:implications for early identification and intervention" 19 : 280-293, 2009
• 101 Friedman RA, "Expanding the black boxdepression, antidepressants, and the risk of suicide" 356 : 2343-2346, 2007
• 102 Dunn AL, "Exercise treatment for depression: efficacy and dose response" 28 : 1-8, 2005
• 103 Lewandowski KE, "Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder" 41 : 225-241, 2011
• 104 Berger GE, "Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial" 68 : 1867-1875, 2007
• 105 Petersen T, "Empirical testing of two models for staging antidepressant treatment resistance" 25 : 336-341, 2005
• 106 Miklowitz DJ, "Early psychosocial intervention for youth at risk for bipolar I or II disorder:a one-year treatment development trial" 13 : 67-75, 2011
• 107 Parker G, "Early onset depression:the relevance of anxiety" 32 : 30-37, 1997
• 108 Benarous X, "Early interventions for youths at high risk for bipolar disorder:a developmental approach" 25 : 217-233, 2016
• 109 Miklowitz DJ, "Early intervention for symptomatic youth at risk for bipolar disorder: a randomized trial of family-focused therapy" 52 : 121-131, 2013
• 110 Goldstein TR, "Early intervention for adolescents at high risk for the development of bipolar disorder: pilot study of Interpersonal and Social Rhythm Therapy (IPSRT)" 51 : 180-189, 2014
• 111 Hetrick SE, "Early identification and intervention in depressive disorders: towards a clinical staging model" 77 : 263-270, 2008
• 112 Norman RM, "Duration of untreated psychosis:a critical examination of the concept and its importance" 31 : 381-400, 2001
• 113 Findling RL, "Double-blind, placebo-controlled trial of divalproex monotherapy in the treatment of symptomatic youth at high risk for developing bipolar disorder" 68 : 781-788, 2007
• 114 Chang KD, "Divalproex monotherapy in the treatment of bipolar offspring with mood and behavioral disorders and at least mild affective symptoms" 64 : 936-942, 2003
• 115 American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-5" American Psychiatric Association 2013
• 116 American Psychiatric Association, "Diagnostic and statistical manual of mental disorders : [DSM III]" APA 1980
• 117 Patterson C, "Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease" 178 : 548-556, 2008
• 118 Fava M, "Diagnosis and definition of treatment-resistant depression" 53 : 649-659, 2003
• 119 Eckblad M, "Development and validation of a scale for hypomanic personality" 95 : 214-222, 1986
• 120 Wright A, "Development and evaluation of a youth mental health community awareness campaign - The Compass Strategy" 6 : 2006
• 121 Belleville S, "Detecting early preclinical Alzheimer’s disease via cognition, neuropsychiatry, and neuroimaging:qualitative review and recommendations for testing" 42 (42): S375-S382, 2014
• 122 American Psychiatric Association, "Desk reference to the diagnostic criteria from DSM-5" American Psychiatric Publishing 2013
• 123 Berlim MT, "Definition, assessment, and staging of treatment-resistant refractory major depression:a review of current concepts and methods" 52 : 46-54, 2007
• 124 Shumaker SA, "Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study" 291 : 2947-2958, 2004
• 125 Walhovd KB, "Combining MR Imaging, Positron-Emission Tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease" 31 : 347-354, 2010
• 126 Morrison AP, "Cognitive therapy for the prevention of psychosis in people at ultra-high risk" 185 : 291-297, 2004
• 127 Walkup JT, "Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety" 359 : 2753-2766, 2008
• 128 Murphy GE, "Cognitive behavior therapy, relaxation training, and tricyclic antidepressant medication in the treatment of depression" 77 : 403-420, 1995
• 129 Pike KE, "Cognition and beta-amyloid in preclinical Alzheimer’s disease: data from the AIBL study" 49 : 2384-2390, 2011
• 130 McGorry PD, "Clinical staging: a heuristic model for psychiatry and youth mental health" 187 : 2-, 2007
• 131 McGorry PD, "Clinical staging: a heuristic and practical strategy for new research and better health and social outcomes for psychotic and related mood disorders" 55 : 486-497, 2010
• 132 McGorry PD, "Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions" 40 : 616-622, 2006
• 133 Verduijn J, "Clinical staging of major depressive disorder: an empirical exploration" 76 : 1200-1208, 2015
• 134 Lin A, "Clinical staging in severe mental disorder: evidence from neurocognition and neuroimaging" 54 : s11-s17, 2013
• 135 Lewinsohn PM, "Clinical implications of “subthreshold” depressive symptoms" 109 : 345-, 2000
• 136 Kapczinski F, "Clinical implications of a staging model for bipolar disorders" 9 : 957-966, 2009
• 137 Kim KR, "Clinical efficacy of individual cognitive therapy in reducing psychiatric symptoms in people at ultrahigh risk for psychosis" 5 : 174-178, 2011
• 138 McKhann G, "Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease" 34 : 939-944, 1984
• 139 Nadkarni RB, "Clinical course of children with a depressive spectrum disorder and transient manic symptoms" 12 : 494-503, 2010
• 140 Wilcox HC, "Child and adolescent clinical features as forerunners of adult-onset major depressive disorder: retrospective evidence from an epidemiological sample" 82 : 9-20, 2004
• 141 Papachristou E, "Child Behavior Checklist-Mania Scale (CBCL-MS): Development and evaluation of a population-based screening scale for bipolar disorder" 8 : e69459-, 2013
• 142 Bordin IA, "Child Behavior Checklist (CBCL),Youth Self-Report (YSR) and Teacher’s Report Form(TRF): an overview of the development of the original and Brazilian versions" 29 : 13-28, 2013
• 143 Chen KW, "Characterizing Alzheimer’s disease using a hypometabolic convergence index" 56 : 52-60, 2011
• 144 Mathalon DH, "Challenges associated with application of clinical staging models to psychotic disorders" 70 : 600-601, 2011
• 145 Häfner H, "Causes and consequences of the gender difference in age at onset of schizophrenia" 24 : 99-113, 1998
• 146 Fusar-Poli P, "Can antidepressants prevent psychosis?" 370 : 1746-1748, 2007
• 147 Cornblatt BA, "Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents" 68 : 1-478, 2007
• 148 Weissman MM, "Brief screening for family psychiatric history: the family history screen" 57 : 675-682, 2000
• 149 McGorry P, "Biomarkers and clinical staging in psychiatry" 13 : 211-223, 2014
• 150 Carver CS, "Behavioral-inhibition, behavioral activation, and affective responses to impending reward and punishment - the Bis Bas Scales" 67 : 319-333, 1994
• 151 Risacher SL, "Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort" 6 : 347-361, 2009
• 152 McGorry PD, "Back to the future: predicting and reshaping the course of psychotic disorder" 65 : 25-, 2008
• 153 Desikan RS, "Automated MRI measures predict progression to Alzheimer’s disease" 31 : 1364-1374, 2010
• 154 Marshall M, "Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review" 62 : 975-983, 2005
• 155 Carpenter WT, "Anticipating DSM-V: should psychosis risk become a diagnostic class?" 35 : 841-843, 2009
• 156 Atlantis E, "An effective exercise-based intervention for improving mental health and quality of life measures: a randomized controlled trial" 39 : 424-434, 2004
• 157 Rabinovici GD, "Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo" 21 : 117-128, 2009
• 158 Snyder HM, "Alzheimer’s disease research in the context of the national plan to address Alzheimer’s disease" 43-44 : 16-24, 2015
• 159 Takahashi T, "Altered depth of the olfactory sulcus in ultra high-risk individuals and patients with psychotic disorders" 153 : 18-24, 2014
• 160 Prichard JC, "A treatise on insanity and other disorders affecting the mind" E. L. Carey & A. Hart 1837
• 161 Picardi A, "A randomised controlled trial of the effectiveness of a program for early detection and treatment of depression in primary care" 198 : 96-101, 2016
• 162 Hughes CP, "A new clinical scale for the staging of dementia" 140 : 566-572, 1982
• 163 Fekadu A, "A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method" 70 : 177-184, 2009
• 164 Stice E, "A meta-analytic review of depression prevention programs for children and adolescents: factors that predict magnitude of intervention effects" 2009
• 165 Kwapil TR, "A longitudinal study of high scorers on the hypomanic personality scale" 109 : 222-226, 2000
• 166 Espinosa A, "A longitudinal followup of 550 mild cognitive impairment patients: evidence for large conversion to dementia rates and detection of major risk factors involved" 34 : 769-780, 2013
• 167 Reynolds WM, "A comparison of cognitivebehavioral therapy and relaxation training for the treatment of depression in adolescents" 54 : 653-, 1986
• 168 DelBello MP, "A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder" 68 : 789-795, 2007
• 169 Madsen SK, "3D maps localize caudate nucleus atrophy in 400 Alzheimer’s disease, mild cognitive impairment, and healthy elderly subjects" 31 : 1312-1325, 2010